Repercussions of COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer diagnosis and neoadjuvant treatment over patients’ quality of life and mental health/ Repercussões dos impactos da pandemia COVID-19 no diagnóstico e tratamento neoadjuvante de câncer de mama HER2-negativo não metastático sobre a qualidade de vida e saúde mental das pacientes
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Health Review |
Texto Completo: | https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/46807 |
Resumo: | OBJECTIVE: To understand if COVID-19 pandemic impacts on delays in non-metastatic HER2-negative breast cancer diagnosis and in the beginning/development of neoadjuvant chemotherapy, as well as on changes in treatment plan to Paclitaxel intensification doses, impaired patients’ quality of life and mental health. METHODS: This is a cross-sectional study of 67 women diagnosed with non-metastatic HER2-negative breast cancer during the first sixteen months of COVID-19 pandemic and receiving neoadjuvant treatment due to pandemic impossibility of immediate definitive cancer surgery following the neoplasm diagnosis. Sociodemographic, Functional Assessment of Cancer Therapy Scale - General, Beck Anxiety and Depression Inventory were used for outcomes assessment. Inferential analysis was performed by Mann-Whitney, Pearson's chi-squared, and Fisher's exact tests. The adopted significance was 5%. RESULTS: The study revealed that the oncological diagnosis delays caused a worsening of the patients' physical (8 x 21; p = 0.001), functional (13 x 21; p = 0.03) and general (61 x 83; p = 0.004) well-being; retardment in the beginning of neoadjuvant chemotherapy decreased physical well-being (13 x 21; p = 0.01). Changes in treatment plan, to Paclitaxel doses intensification, had a negative effect on functional well-being (20 x 25.5; p = 0.04). COVID-19 pandemic impacts on neoplasm diagnosis and neoadjuvant treatment delays were also associated with psychosocial manifestations, including higher levels of severe anxiety (60% x 14.5%; p = 0.03 and 40% x 14%; p = 0.04) and depression (40% x 3.2%; p = 0.004 and 60% x 5.3%; p = 0.03) respectively. CONCLUSION: The present study shows that COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer patients’ diagnosis and neoadjuvant chemotherapy impaired patients' quality of life and mental health. |
id |
BJRH-0_b01ec74e1c89c63a55e46c73f8a32c61 |
---|---|
oai_identifier_str |
oai:ojs2.ojs.brazilianjournals.com.br:article/46807 |
network_acronym_str |
BJRH-0 |
network_name_str |
Brazilian Journal of Health Review |
repository_id_str |
|
spelling |
Repercussions of COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer diagnosis and neoadjuvant treatment over patients’ quality of life and mental health/ Repercussões dos impactos da pandemia COVID-19 no diagnóstico e tratamento neoadjuvante de câncer de mama HER2-negativo não metastático sobre a qualidade de vida e saúde mental das pacientesbreast neoplasmsCOVID-19mental healthanxietydepressionOBJECTIVE: To understand if COVID-19 pandemic impacts on delays in non-metastatic HER2-negative breast cancer diagnosis and in the beginning/development of neoadjuvant chemotherapy, as well as on changes in treatment plan to Paclitaxel intensification doses, impaired patients’ quality of life and mental health. METHODS: This is a cross-sectional study of 67 women diagnosed with non-metastatic HER2-negative breast cancer during the first sixteen months of COVID-19 pandemic and receiving neoadjuvant treatment due to pandemic impossibility of immediate definitive cancer surgery following the neoplasm diagnosis. Sociodemographic, Functional Assessment of Cancer Therapy Scale - General, Beck Anxiety and Depression Inventory were used for outcomes assessment. Inferential analysis was performed by Mann-Whitney, Pearson's chi-squared, and Fisher's exact tests. The adopted significance was 5%. RESULTS: The study revealed that the oncological diagnosis delays caused a worsening of the patients' physical (8 x 21; p = 0.001), functional (13 x 21; p = 0.03) and general (61 x 83; p = 0.004) well-being; retardment in the beginning of neoadjuvant chemotherapy decreased physical well-being (13 x 21; p = 0.01). Changes in treatment plan, to Paclitaxel doses intensification, had a negative effect on functional well-being (20 x 25.5; p = 0.04). COVID-19 pandemic impacts on neoplasm diagnosis and neoadjuvant treatment delays were also associated with psychosocial manifestations, including higher levels of severe anxiety (60% x 14.5%; p = 0.03 and 40% x 14%; p = 0.04) and depression (40% x 3.2%; p = 0.004 and 60% x 5.3%; p = 0.03) respectively. CONCLUSION: The present study shows that COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer patients’ diagnosis and neoadjuvant chemotherapy impaired patients' quality of life and mental health.Brazilian Journals Publicações de Periódicos e Editora Ltda.2022-04-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/4680710.34119/bjhrv5n2-265Brazilian Journal of Health Review; Vol. 5 No. 2 (2022); 7002-7019Brazilian Journal of Health Review; v. 5 n. 2 (2022); 7002-70192595-6825reponame:Brazilian Journal of Health Reviewinstname:Federação das Indústrias do Estado do Paraná (FIEP)instacron:BJRHenghttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/46807/pdfCopyright (c) 2022 Brazilian Journal of Health Reviewinfo:eu-repo/semantics/openAccessKemer, Glendha de SousaNeto, Ricardo PasquiniKarvat, João Gabriel VicentiniSilveira, Isabela Hodecker daBornia, Maria Júlia PilauMorila, Mariana Cristina GomesMagalhães, Maria Cristina Figueroa2022-05-02T19:47:11Zoai:ojs2.ojs.brazilianjournals.com.br:article/46807Revistahttp://www.brazilianjournals.com/index.php/BJHR/indexPRIhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/oai|| brazilianjhr@gmail.com2595-68252595-6825opendoar:2022-05-02T19:47:11Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP)false |
dc.title.none.fl_str_mv |
Repercussions of COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer diagnosis and neoadjuvant treatment over patients’ quality of life and mental health/ Repercussões dos impactos da pandemia COVID-19 no diagnóstico e tratamento neoadjuvante de câncer de mama HER2-negativo não metastático sobre a qualidade de vida e saúde mental das pacientes |
title |
Repercussions of COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer diagnosis and neoadjuvant treatment over patients’ quality of life and mental health/ Repercussões dos impactos da pandemia COVID-19 no diagnóstico e tratamento neoadjuvante de câncer de mama HER2-negativo não metastático sobre a qualidade de vida e saúde mental das pacientes |
spellingShingle |
Repercussions of COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer diagnosis and neoadjuvant treatment over patients’ quality of life and mental health/ Repercussões dos impactos da pandemia COVID-19 no diagnóstico e tratamento neoadjuvante de câncer de mama HER2-negativo não metastático sobre a qualidade de vida e saúde mental das pacientes Kemer, Glendha de Sousa breast neoplasms COVID-19 mental health anxiety depression |
title_short |
Repercussions of COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer diagnosis and neoadjuvant treatment over patients’ quality of life and mental health/ Repercussões dos impactos da pandemia COVID-19 no diagnóstico e tratamento neoadjuvante de câncer de mama HER2-negativo não metastático sobre a qualidade de vida e saúde mental das pacientes |
title_full |
Repercussions of COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer diagnosis and neoadjuvant treatment over patients’ quality of life and mental health/ Repercussões dos impactos da pandemia COVID-19 no diagnóstico e tratamento neoadjuvante de câncer de mama HER2-negativo não metastático sobre a qualidade de vida e saúde mental das pacientes |
title_fullStr |
Repercussions of COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer diagnosis and neoadjuvant treatment over patients’ quality of life and mental health/ Repercussões dos impactos da pandemia COVID-19 no diagnóstico e tratamento neoadjuvante de câncer de mama HER2-negativo não metastático sobre a qualidade de vida e saúde mental das pacientes |
title_full_unstemmed |
Repercussions of COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer diagnosis and neoadjuvant treatment over patients’ quality of life and mental health/ Repercussões dos impactos da pandemia COVID-19 no diagnóstico e tratamento neoadjuvante de câncer de mama HER2-negativo não metastático sobre a qualidade de vida e saúde mental das pacientes |
title_sort |
Repercussions of COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer diagnosis and neoadjuvant treatment over patients’ quality of life and mental health/ Repercussões dos impactos da pandemia COVID-19 no diagnóstico e tratamento neoadjuvante de câncer de mama HER2-negativo não metastático sobre a qualidade de vida e saúde mental das pacientes |
author |
Kemer, Glendha de Sousa |
author_facet |
Kemer, Glendha de Sousa Neto, Ricardo Pasquini Karvat, João Gabriel Vicentini Silveira, Isabela Hodecker da Bornia, Maria Júlia Pilau Morila, Mariana Cristina Gomes Magalhães, Maria Cristina Figueroa |
author_role |
author |
author2 |
Neto, Ricardo Pasquini Karvat, João Gabriel Vicentini Silveira, Isabela Hodecker da Bornia, Maria Júlia Pilau Morila, Mariana Cristina Gomes Magalhães, Maria Cristina Figueroa |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Kemer, Glendha de Sousa Neto, Ricardo Pasquini Karvat, João Gabriel Vicentini Silveira, Isabela Hodecker da Bornia, Maria Júlia Pilau Morila, Mariana Cristina Gomes Magalhães, Maria Cristina Figueroa |
dc.subject.por.fl_str_mv |
breast neoplasms COVID-19 mental health anxiety depression |
topic |
breast neoplasms COVID-19 mental health anxiety depression |
description |
OBJECTIVE: To understand if COVID-19 pandemic impacts on delays in non-metastatic HER2-negative breast cancer diagnosis and in the beginning/development of neoadjuvant chemotherapy, as well as on changes in treatment plan to Paclitaxel intensification doses, impaired patients’ quality of life and mental health. METHODS: This is a cross-sectional study of 67 women diagnosed with non-metastatic HER2-negative breast cancer during the first sixteen months of COVID-19 pandemic and receiving neoadjuvant treatment due to pandemic impossibility of immediate definitive cancer surgery following the neoplasm diagnosis. Sociodemographic, Functional Assessment of Cancer Therapy Scale - General, Beck Anxiety and Depression Inventory were used for outcomes assessment. Inferential analysis was performed by Mann-Whitney, Pearson's chi-squared, and Fisher's exact tests. The adopted significance was 5%. RESULTS: The study revealed that the oncological diagnosis delays caused a worsening of the patients' physical (8 x 21; p = 0.001), functional (13 x 21; p = 0.03) and general (61 x 83; p = 0.004) well-being; retardment in the beginning of neoadjuvant chemotherapy decreased physical well-being (13 x 21; p = 0.01). Changes in treatment plan, to Paclitaxel doses intensification, had a negative effect on functional well-being (20 x 25.5; p = 0.04). COVID-19 pandemic impacts on neoplasm diagnosis and neoadjuvant treatment delays were also associated with psychosocial manifestations, including higher levels of severe anxiety (60% x 14.5%; p = 0.03 and 40% x 14%; p = 0.04) and depression (40% x 3.2%; p = 0.004 and 60% x 5.3%; p = 0.03) respectively. CONCLUSION: The present study shows that COVID-19 pandemic impacts on non-metastatic HER2-negative breast cancer patients’ diagnosis and neoadjuvant chemotherapy impaired patients' quality of life and mental health. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-04-20 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/46807 10.34119/bjhrv5n2-265 |
url |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/46807 |
identifier_str_mv |
10.34119/bjhrv5n2-265 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/46807/pdf |
dc.rights.driver.fl_str_mv |
Copyright (c) 2022 Brazilian Journal of Health Review info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2022 Brazilian Journal of Health Review |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Brazilian Journals Publicações de Periódicos e Editora Ltda. |
publisher.none.fl_str_mv |
Brazilian Journals Publicações de Periódicos e Editora Ltda. |
dc.source.none.fl_str_mv |
Brazilian Journal of Health Review; Vol. 5 No. 2 (2022); 7002-7019 Brazilian Journal of Health Review; v. 5 n. 2 (2022); 7002-7019 2595-6825 reponame:Brazilian Journal of Health Review instname:Federação das Indústrias do Estado do Paraná (FIEP) instacron:BJRH |
instname_str |
Federação das Indústrias do Estado do Paraná (FIEP) |
instacron_str |
BJRH |
institution |
BJRH |
reponame_str |
Brazilian Journal of Health Review |
collection |
Brazilian Journal of Health Review |
repository.name.fl_str_mv |
Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP) |
repository.mail.fl_str_mv |
|| brazilianjhr@gmail.com |
_version_ |
1797240074033692672 |